Metsera has technologies and drug candidates intended to improve on these limitations. With key clinical trial readouts expected this year, the company took its story to investors through an IPO.

After an IPO this year, Metsera is making its best effort to catch up to obesity drug giants Eli Lilly and Novo Nordisk. Endpoints caught up with CEO Whit Bernard to discuss what's next for the ...

Metsera ,” said Whit Bernard, CEO. “We advanced MET-097i, our monthly, fully-biased GLP-1 RA injectable, from f ...

Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

With the completion of our recent IPO, we have substantial capital to ... as we rapidly advance Metsera’s portfolio of ultra-long acting, scalable and combinable injectable and oral candidates.” ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the ...

In February, Metsera completed an IPO, raising approximately $316.2 million in aggregate gross proceeds from the offering before deducting underwriting discounts, commissions and other offering ...

Recent Business Highlights Completed initial public offering (IPO) In February, Metsera completed an IPO, raising approximately $316.2 million in aggregate gross proceeds from the offering before ...